Nervous Disorder TRIZ Cases

A composition combining oleuropein and vitamin B6 enhances mitochondrial energy production.

Specialized tryptophan feed boosts egg yolk AF protein concentration, resolving low therapeutic yield from standard poultry diets.

Viral vectors carrying DLX transcription factors reprogram resident glial cells into neural progenitors, generating neurons, astrocytes, and oligodendrocytes.

Segmenting diagnostic approaches by specific CD44 splice variants resolves the contradiction between general detection and precise mechanistic identification.

Local variable region humanization reduces immunogenicity while maintaining binding strength.

Broadly neutralizing monoclonal antibodies target interferon-alpha and omega to suppress the type I interferon signature in systemic lupus erythematosus.

CD34+ bone marrow-derived cells stimulate angiogenesis to address disc degeneration progression by enhancing perfusion and reducing inflammation.

Lactoferrin inhibits microglial activation and oxidative stress to reduce Tau phosphorylation and cognitive decline.

A specific GCS inhibitor compound blocks glucose transfer to ceramide.

Metabolite biomarkers detect mild traumatic brain injury via breath condensate analysis, resolving low diagnostic sensitivity in clinical assessments.

LRP10 inhibition accelerates hematopoietic recovery after chemotherapy while promoting CD8+ T cell infiltration into tumors.

Extracting stem cells from discarded umbilical cord waste to provide a reliable, ethically acceptable source for regenerative medicine therapies.

2,6-dioxaspiro[4,5]decane derivatives selectively activate the Gi signaling pathway to reduce beta-arrestin side effects.

4-O-methylhonokiol reduces beta-amyloid production to treat Alzheimer's disease without liver toxicity.

Optimized culture conditions convert cysteine to formylglycine in recombinant iduronate-2-sulfatase, resolving low efficacy of Elaprase.

Modular heterocyclic compounds activate orexin type 2 receptors, expanding therapeutic options for narcolepsy and sleep disorders.

High-dose crenezumab reduces amyloid beta levels while minimizing ARIA risk in early Alzheimer's patients.

Single transcript expression cassette combines shRNA silencing with replacement protein production to resolve stability challenges in post-mitotic neurons.

Merges extended-release levetiracetam with donepezil to prolong therapeutic effects while minimizing side effects from peak drug concentrations.

Weak promoter-driven CLN3 expression restores lysosomal function without cellular toxicity, treating juvenile batten disease.

Ester prodrugs of tramiprosate cross the blood-brain barrier to inhibit amyloid-beta aggregation and reduce plaque build-up in Alzheimer's disease.

A blood-brain barrier shuttle links therapeutic antibodies to receptor binders for brain delivery.

Glibenclamide blocks SUR1-associated ion channels, reducing neuronal cell death and ameliorating dementia symptoms.

Bryostatin-1 and MCBA activate PKC signaling to boost NGF and BDNF levels, addressing memory deficits when treatment starts hours post-injury.

Acetylcholinesterase inhibitors promote myelin regeneration in leukodystrophy models through sigma-1 receptor agonism.

Small molecule EphA4 inhibitors reduce amyloid plaque formation and improve synaptic plasticity in neurodegenerative disease treatment.

Monoclonal antibodies bind acetylated lysine 280 and 311 on human tau protein for targeted detection.

A tricyclic compound targets dopamine D2 and 5-HT1A receptors to treat mental diseases.

A pharmaceutical compound modulates Nurr1 receptor activity to increase dopamine levels and improve motor function in patients.

Xanthohumol reduces inflammatory damage by blocking macrophage infiltration, accelerating edema elimination, and improving neurological function recovery.

Engineered promoter system controls transcription level of payload sequence via recombinant transcription factor binding polynucleotide.

A Laurus nobilis leaf extract composition rapidly lowers blood alcohol and acetaldehyde concentrations.

Integrin beta1-derived polypeptides neutralize amyloid beta 1-42 toxicity by preventing Rac1 activation and reactive oxygen species formation in astrocytes.

Autologous iPSC-derived neural precursors replace defective oligodendrocytes to reduce NAA levels and improve myelination without viral vector tolerance issues.

Hydrocarbon stapling stabilizes alpha-helical peptides against proteolysis, resolving the trade-off between helical reliability and cellular penetration.

Formula I sulfonamide compounds modulate the orexin-2 receptor to treat sleep disorders.

A CD38-binding compound activates NAADP receptors to increase cytosolic calcium levels and protect neurons from degeneration.

Combining PDE7 inhibitors with dopaminergic agents targets specific enzyme pathways to decrease relapse rates and improve therapeutic efficacy.

Plexin D1 targeting overcomes mature vasculature insensitivity by disrupting tumor blood supply and inhibiting metastatic progression.

GHB salt formulations replace sodium cations with potassium, calcium, or magnesium to maintain therapeutic efficacy.

Conjugating fentanyl haptens to CRM197 with adjuvants overcomes low antibody variability, blocking lethal effects.

Atacicept targets BLyS and APRIL ligands to reduce mature B cells, resolving severe side effects from standard autoimmune therapies.

Ethynylbenzyl heterocycles improve oral bioavailability and brain penetrance to treat narcolepsy.

Intranasal Forskolin and Noopept reverse neuronal loss by restoring mitochondrial function.

Tick-derived histamine binding protein blocks peripheral histamine receptors to relieve neuropathic pain without central nervous system side effects.

QBP1 peptide targets Orb2 prion-like domains to inhibit traumatic memory consolidation without erasing unrelated memories.